Podium to Practice: Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data_Updates from the 2021 ASCO and EHA Annual Meetings


Navigating the New Landscape in Relapsed/Refractory Multiple Myeloma – Clinical Impact of Recently Presented Data
Updates from the 2021 ASCO and EHA Annual Meetings

Release Date: August 19, 2021
Expiration Date: August 18, 2022

Activity Overview

Watch this accredited continuing education discussion featuring two multiple myeloma experts as they provide expert summary and guidance on the optimal use of current and emerging therapies and interpretation of data presented during the 2021 ASCO and EHA Annual Meetings.

Target Audience
The target audience for this activity is c
ommunity and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.

Learning Objectives
After participating in this activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse

  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy

  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM

  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Disclosure Declaration
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty Disclosures
All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Cristina Gasparetto, MD (Moderator)
Professor of Medicine, Hematologic Malignancies and Cellular Therapy
Duke University School of Medicine
Durham, North Carolina

Maria-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing

This activity is supported by independent educational grants from
AbbVie Inc., Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Sanofi Genzyme

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.